rosiglitazone + glimepiride

**Rosiglitazone + glimepiride** is an oral fixed-dose antidiabetic combination containing rosiglitazone, a thiazolidinedione insulin sensitizer, and glimepiride, a sulfonylurea insulin secretagogue. Rosiglitazone activates peroxisome proliferator-activated receptor gamma to improve insulin sensitivity in adipose tissue, skeletal muscle, and liver, while glimepiride stimulates pancreatic beta-cell insulin release through inhibition of ATP-sensitive potassium channels. The combination was developed by GSK for glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise and was marketed as Avandaryl in the United States and Avaglim in Europe. It carries clinically important risks associated with its components, including hypoglycemia from glimepiride and fluid retention and heart-failure risk from rosiglitazone. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021700s008lbl.pdf))

Brand names

Avaglim

Other names

glimepiride + rosiglitazoneglimepiride/rosiglitazonerosiglitazone + glimepiriderosiglitazone maleate + glimepiriderosiglitazone/glimepiride